Analysts Issue Forecasts for Aytu BioPharma Q1 Earnings

Aytu BioPharma Inc. (NASDAQ:AYTU) – Stock analysts at Ascendiant Capital Markets issued their Q1 2028 earnings per share (EPS) estimates for Aytu BioPharma in a research note issued on Tuesday, September 29th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will post earnings per share of $0.01 for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $14.50 price target on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is $0.25 per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q2 2028 earnings at $0.00 EPS, Q3 2028 earnings at $0.03 EPS, Q4 2028 earnings at $0.10 EPS and FY2028 earnings at $0.14 EPS.

Several other equities research analysts also recently weighed in on the company. Weiss Ratings raised Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a report on Tuesday, September 22nd. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, Citigroup reissued a “positive” rating on shares of Aytu BioPharma in a research note on Tuesday, September 22nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $14.50.

Aytu BioPharma Stock Down 1.4%

Aytu BioPharma stock opened at $2.04 on Monday. Aytu BioPharma has a twelve month low of $1.80 and a twelve month high of $3.07. The stock has a 50 day moving average of $2.22 and a two-hundred day moving average of $2.30. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $22.17 million, a price-to-earnings ratio of -1.23 and a beta of 0.17.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AYTU. Nantahala Capital Management LLC acquired a new stake in shares of Aytu BioPharma in the second quarter valued at about $2,336,646. Stonepine Capital Management LLC acquired a new position in Aytu BioPharma during the second quarter worth about $1,962,780. AWM Investment Company Inc. acquired a new position in Aytu BioPharma during the second quarter worth about $1,332,000. Crown Advisors Management Inc. purchased a new position in Aytu BioPharma in the second quarter valued at about $430,000. Finally, Arete Wealth Advisors LLC purchased a new position in Aytu BioPharma in the first quarter valued at about $135,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.